A Phase 4 interventional study of Fang Le Shu (Follitrope) and Guo Na Fen (Gonal-F) in Female Infertility, sponsored by LG Chem. Active, not recruiting at 1 site in China. Open to female participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by LG Chem · Phase 4, Interventional, and Treatment
The aim of this randomized, open-label, active-controlled, parallel-group, multicenter, phase IV study is to assess the efficacy and safety of Fang Le Shu versus Guo Na Fen used for controlled ovarian stimulation in infertile women undergoing In Vitro Fertilization-Embryo Transfer.
540 studies on the registry are indexed under Infertility, Female; 138 are open to participants now.
This study's planned enrollment of 248 is above the median of 100 across 371 interventional studies indexed under Infertility, Female.
Browse Infertility, Female studies →LG Chem is the lead sponsor of 70 studies on the registry; 8 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Fang Le Shu
Drug: Fang Le Shu (Follitrope)
Guo Na Fen
Drug: Guo Na Fen (Gonal-F)
rFSH 150 IU, 225 IU, 300 IU per syringe
rFSH 450 IU per pen
Number of oocytes retrieved
Time frame: 36 ± 3 hours after HGC trigger
High quality embryo rate
Time frame: 3 days after oocyte retrieval
Biochemical pregnancy rate
Time frame: 14 days after embryo transfer
Clinical pregnancy rate
Time frame: 5 weeks after embryo transfer
Ongoing pregnancy rate
Time frame: 10 weeks after embryo transfer
Miscarriage rate
Time frame: 28 weeks of gestation
Live birth rate
Time frame: 40 weeks of gestation
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
LG Chem